title: Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?
authors.affiliation: Department of Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
authors.forename: Elie
authors.initials: E
authors.lastname: El Rassy
authors.affiliation: Department of Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
authors.forename: Tarek
authors.initials: T
authors.lastname: Assi
authors.affiliation: Department of Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
authors.forename: Joseph
authors.initials: J
authors.lastname: Kattan
mesh_terms: D006801:Humans; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D056747:Immunomodulation / Q000187:drug effects; D058990:Molecular Targeted Therapy; D018365:Neoplasm, Residual / Q000473:pathology; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D060908:CTLA-4 Antigen; D061026:Programmed Cell Death 1 Receptor
keywords: circulating tumor cells; immune checkpoint inhibitors; minimal residual disease